Cogent Presents Results of Bezuclastinib in P-II (APEX) Trial for the Treatment of Advanced Systemic Mastocytosis at EHA 2022
- The P-II (APEX) trial evaluated bezuclastinib in patients with AdvS. The updated data will be expected at the end of 2022
- As of the data cutoff date of May 2022, 11 patients were evaluated for signs of clinical activity, all patients achieved a ≥50% reduction in serum tryptase levels with a median reduction of 89% & 6 achieved a reduction to <20 ng/mL. All 8 bone marrow biopsy-assessed patients achieved ≥50% bone marrow mast cells reduction & 6 with complete clearance
- 8 patients showed a reduction in KIT D816V VAF, 3 discontinued avapritinib for toxicity reasons, clinical outcomes consistent with avapritinib-naïve patients, were well-tolerated with no reported periorbital or peripheral edema, cognitive effects, or intracranial bleeding events
Ref: Globenewswire | Image: Cogent
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.